Evicenter
P&T meetings

BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer
SpyGlass Pharma
Regulatory submission
NDA planned for 2028
Launch
Not announced
Last updated
129 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Open-angle glaucoma or ocular hypertension

Economic impact of diagnostic testing

6 evidence topics · 6 sources

Medicare Part B payments: optical coherence tomography of the optic nerve (CPT 92133), 2024
FieldOffice and other non-facility settingsFacility settings
Service description“Imaging of optic nerve”“Imaging of optic nerve”
Place of service code“O”“F”
Total beneficiaries“2353950”“59478”
Total services“2704197.1”“67036”
Average submitted charge (USD)“111.02944985”“107.26792037”
Average Medicare allowed amount (USD)“34.480219382”“21.326738021”
Average Medicare payment amount (USD)“24.047622387”“14.822967212”
Medicare Part B payments: extended visual field examination (CPT 92083), 2024
FieldOffice and other non-facility settingsFacility settings
Service description“Exam of visual field with extended testing”“Exam of visual field with extended testing”
Place of service code“O”“F”
Total beneficiaries“2256481”“57345”
Total services“2654750”“67503”
Average submitted charge (USD)“150.1505657”“121.66678933”
Average Medicare allowed amount (USD)“62.079533207”“26.88252611”
Average Medicare payment amount (USD)“43.643536035”“18.909151741”